GRACE Score — Complete Clinical Guide
The GRACE (Global Registry of Acute Coronary Events) score was derived from a prospective multinational registry of over 43,000 patients with ACS across 14 countries. It was developed to provide clinicians with an objective, validated tool for risk stratification of patients presenting with acute coronary syndrome — enabling evidence-based decisions about invasive strategy timing, discharge planning, and intensity of secondary prevention. The GRACE score predicts both in-hospital and post-discharge mortality, making it uniquely valuable for the full spectrum of ACS management from admission through 6 months.
The eight components of the GRACE score — age, heart rate, systolic blood pressure, serum creatinine, Killip class, cardiac arrest at admission, ST-segment deviation, and elevated cardiac enzymes — were selected from multivariate logistic regression as independent predictors of in-hospital mortality. The score is validated for STEMI, NSTEMI, and unstable angina, though its discriminative accuracy is highest for NSTEMI and unstable angina (AUROC ~0.83).
GRACE Score Risk Categories and Mortality
| Risk Category | GRACE Score | In-Hospital Mortality | 6-Month Mortality | ESC Strategy |
|---|---|---|---|---|
| Low | ≤108 | <1% | <3% | Invasive within 72 hours |
| Intermediate | 109–140 | 1–3% | 3–8% | Invasive within 24 hours |
| High | >140 | >3% | >8% | Invasive within 2 hours |
ESC 2020 NSTEMI — Invasive Strategy Timing Based on GRACE
- Immediate invasive (<2 hours) — Very high-risk NSTEMI: Haemodynamic instability or cardiogenic shock, recurrent or ongoing chest pain refractory to medical treatment, life-threatening arrhythmias, mechanical complications of MI, acute heart failure clearly related to NSTEMI, ST-segment changes >1 mm in ≥6 leads (anterior MI equivalent)
- Early invasive (<24 hours) — High-risk NSTEMI: GRACE score >140, dynamic ST-T changes, rise or fall in troponin consistent with MI
- Invasive within 72 hours — Intermediate-risk NSTEMI: Diabetes mellitus, renal insufficiency (eGFR <60), LVEF <40%, early post-infarction angina, prior PCI or CABG, GRACE score 109–140
- Selective invasive — Low-risk NSTEMI: GRACE score <109, no recurrent symptoms, no high-risk features. Non-invasive stress testing first; angiography if ischaemia confirmed
Antiplatelet Therapy in NSTEMI — ESC 2020
- Aspirin: Loading dose 150–300 mg orally immediately, then 75–100 mg daily indefinitely. First-line in all ACS patients without allergy
- P2Y12 inhibitor (DAPT): Ticagrelor 180 mg loading then 90 mg BD preferred. Prasugrel 60 mg loading then 10 mg OD for PCI.
- Clopidogrel: For patients on oral anticoagulation or where others unavailable.
GRACE Score Limitations
The GRACE score was derived primarily in Western populations and may underestimate risk in South Asian populations. It requires serum creatinine, which may delay initial risk stratification in resource-limited settings. Despite limitations, GRACE remains the most widely validated and used ACS risk score globally and is specifically endorsed by the ESC 2020 NSTEMI guidelines.